Therapeutic strategies for Pseudomonas aeruginosa pneumonia in the myelosuppressed host.
D000380:Agranulocytosis / Q000150:complications*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006168:Guinea Pigs; D007074:Immunoglobulin G / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D009503:Neutropenia / Q000150:complications*; D011014:Pneumonia / Q000150:complications / Q000628:therapy*; D011552:Pseudomonas Infections / Q000150:complications / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology; D013982:Ticarcillin / Q000627:therapeutic use; D014031:Tobramycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D013982:Ticarcillin; D014031:Tobramycin